Therapies Targeting the Signal Pathways of Pheochromocytoma and Paraganglioma

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s219056
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Pheochromocytoma and Paraganglioma: Understanding the Complexities of the Genetic Background

Cancer genetics
Cancer ResearchGeneticsMolecular Biology
2012English

FGF21 Levels in Pheochromocytoma/Functional Paraganglioma

Cancers
Cancer ResearchOncology
2019English

Metabolic Implications of Hypoxia and Pseudohypoxia in Pheochromocytoma and Paraganglioma

Cell and Tissue Research
Forensic MedicinePathologyHistologyCell Biology
2018English

15 YEARS OF PARAGANGLIOMA: Genetics and Mechanism of Pheochromocytoma–paraganglioma Syndromes Characterized by germlineSDHBandSDHDmutations

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2015English

Role of MDH2 Pathogenic Variant in Pheochromocytoma and Paraganglioma Patients

Genetics in Medicine
MedicineGenetics
2018English

Precision Medicine in Pheochromocytoma and Paraganglioma: Current and Future Concepts

Journal of Internal Medicine
Internal Medicine
2016English

Plasma Methoxytyramine: Clinical Utility With Metanephrines for Diagnosis of Pheochromocytoma and Paraganglioma

European Journal of Endocrinology
MedicineEndocrinologyMetabolismDiabetes
2017English

Targeting Aberrant Signal Transduction Pathways in Lung Cancer

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2004English

Mutational Profile and Genotype/Phenotype Correlation of Non-Familial Pheochromocytoma and Paraganglioma

Oncotarget
Oncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy